Welcome to our dedicated page for Journey Medical SEC filings (Ticker: DERM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Journey Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Journey Medical's regulatory disclosures and financial reporting.
Journey Medical Corporation entered into a Third Amendment to its Credit Agreement with SWK Funding LLC, updating the terms of its existing $25.0 million term loan, which has been fully drawn and is treated as a single Term Loan. The amendment extends the loan’s maturity date from December 27, 2027 to June 27, 2028, giving the company more time before final repayment is due.
Beginning in February 2026, the company must make quarterly principal payments equal to 7.5% of the funded Term Loan. However, if total revenue on a trailing twelve‑month basis exceeds $60.0 million as of December 31, 2025 (revised from $70.0 million), principal payments are deferred until February 2027, at which point quarterly payments increase to 10.0% of the funded amount (revised from 15.0%). These changes adjust how quickly the loan is repaid and link the timing and size of payments more closely to the company’s revenue performance.
Journey Medical Corporation entered a new at‑the‑market equity program, signing an At Market Issuance Sales Agreement with B. Riley Securities and Lake Street Capital Markets. Under this arrangement, the company may, at its discretion, offer and sell up to 3,750,000 shares of common stock through or to the agents under its effective Form S‑3 shelf registration and related prospectus supplement.
The agents are entitled to a 3.0% commission on gross proceeds from any share sales and are indemnified by the company, with certain expenses reimbursed. At the same time, Journey Medical terminated its prior at‑the‑market agreement with B. Riley that had allowed sales of up to 4,900,000 shares of common stock, under which 4,121,318 shares were sold from December 30, 2022 to August 28, 2025.
Journey Medical Corp (DERM) insider filing: The reporting person, Claude Maraoui (President & CEO and Director), exercised 1,250,000 stock options dated October 19, 2015, with an exercise price of $0.065 on 08/25/2025, acquiring 1,250,000 common shares. The Form 4 also reports a disposition of 10,877 shares at $7.47 on the same date. The filing corrects a prior administrative error in previously reported beneficial ownership and shows a post-transaction direct beneficial ownership balance of 2,386,713 shares.
Wasatch Advisors LP reports beneficial ownership of 1,152,059 shares of Journey Medical Corp, representing 6.7% of the outstanding common stock. Wasatch holds sole voting power on 1,045,193 shares and sole dispositive power on 1,152,059 shares, indicating direct control over voting and disposition of those holdings.
The filing identifies Wasatch as an investment adviser and states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer, reflecting a passive ownership position.
Journey Medical reported consolidated product revenue of $15.0 million for the quarter ended June 30, 2025, up slightly from $14.9 million a year earlier as the newly launched Emrosi contributed $2.8 million in the quarter while sales of Accutane declined. The company recorded a net loss of $3.8 million for the quarter and $7.9 million for the six months, narrower year-to-date than the prior-year six-month loss of $13.8 million.
At June 30, 2025 the company held $20.3 million in cash, working capital of $10.8 million, total assets of $81.2 million and stockholders' equity of $19.2 million. Debt includes a $25.0 million term loan (net carry amount $25.1 million) with a current portion of $3.75 million and an effective interest rate of about 14.6%. Management discloses substantial doubt about the company’s ability to continue as a going concern due to recurring losses, and gross-to-net reserves increased to $13.9 million, driven by coupon/rebate accruals related to Emrosi.
Journey Medical Corporation furnished a Current Report on Form 8-K stating that on August 12, 2025 the company issued a press release providing a corporate update and announcing its financial results for the three months ended June 30, 2025. The press release is furnished as Exhibit 99.1 to the report and the cover page interactive data file is furnished as Exhibit 104 (iXBRL). The report specifies the furnished information is not being "filed" under the Securities Exchange Act and is not subject to Section 18 liabilities.
The filing notes Journey Medical is an emerging growth company, lists its Nasdaq trading symbol as DERM and includes the registrant's business address and telephone number. The document is signed by Claude Maraoui, Chief Executive Officer, President and Director.